Prolific Machines said its light-controlled biomanufacturing platform more than doubled fed-batch antibody titers, reporting 21 g/L in a 15-day intensified run for a monoclonal antibody. The company attributes the performance to optogenetic control of gene expression, enabling real-time tuning of production. Prolific also reported process robustness metrics including ~87% viability at harvest and a peak viable cell density of roughly 33 million cells/mL. The company’s stated goal is to reach 25 g/L in fed-batch by the end of 2026, targeting next-generation complex biologics where conventional yields often lag.